Capitalizing on the Growth Potential of Orthobiologics
Dr. Scott Bruder, Founder and CEO of Bruder Consulting and Venture Group, discusses the promise and pitfalls of the orthobiologics market. Nov 01 2022,
Invaluable Advice on What it Takes to Bring Orthobiologics to Market
Working with a team of experts is an important part of the product development process and commercialization efforts. Nov 20 2023,
6 Orthopedic Trends You Can’t Ignore
3D printing, robotics, regenerative medicine and minimally invasive surgery are among the trends that orthopedic veterans say you must consider to remain relevant in the next decade. Mar 26 2020,
New Warning from FDA: Sales of Unapproved Orthobiologic Products
FDA doubled down on its enforcement commitment for Human Cell and Tissue Products after its enforcement discretion ended in May. Jun 22 2021,
Lack of Clinical Evidence Leaves Questions about Orthobiologic Development and Promotion
In the race to capitalize on patient-driven interest in stem cells, biologic and regenerative solutions, there has been an explosion of offerings that lack scientific controls, validity and meaningful evidence. Companies now have until November 2020 to comply with new FDA regulations. Enforcement, that Scott Bruder argues, will return orthobiologics to a state of more principled product promotion and patient care. Dec 02 2019,